Xcovery is a pharmaceutical company dedicated to developing innovative oncology therapies aimed at improving the quality of life for patients with advanced cancer. The company focuses on creating targeted treatments that are not only more effective but also less toxic than existing options. Two of their leading investigational drugs are ensartinib and vorolanib. Ensartinib is a potent ALK inhibitor designed for the first-line treatment of ALK-positive non-small cell lung cancer (NSCLC), showing promising clinical activity in trials. Vorolanib, on the other hand, is a next-generation multikinase inhibitor that targets angiogenesis, making it a valuable candidate for combination therapies in various cancers.

Xcovery's research emphasizes the importance of developing next-generation tyrosine kinase inhibitors (TKIs) that can address the challenges of treatment resistance in cancer therapy. By utilizing agents with different mechanisms of action, Xcovery aims to enhance clinical benefits and reduce the risk of relapse. The company is actively participating in clinical trials, including collaborations with the National Cancer Institute, to expedite the development of their investigational agents. Their strategic focus on combination therapies reflects a commitment to tackling the complexity of cancer treatment, as combinations often yield better outcomes than single-agent therapies.

United States

Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases.

Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com 

Xcovery

Company Details